Innate Pharma, Sobi Partner on Late-Stage Study for Lacutamab
MT Newswires Live
Aug 10
Innate Pharma (IPHA) has partnered with Swedish Orphan Biovitrum, or Sobi, to launch a confirmatory phase 3 study in cutaneous T-cell lymphoma, the companies said Monday.
Under the deal, Innate will run the trial, while Sobi will gain exclusive global commercialization rights for lacutamab upon potential accelerated approval in Sezary syndrome, a subtype of cutaneous T cell lymphoma, they said.
Innate will receive $75 million at closing, up to $40 million in potential near-term milestones, and up to $465 million in additional regulatory, commercial and development milestones, plus sales royalties.
Closing is subject to antitrust clearance and other conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.